he Finnish company Faron Pharmaceuticals Ltd has obtained positive headline data from the Phase II part of the clinical study FPCLI001. These data indicate that the use of the FP-1201 dose regimen in acute lung injury (ALI) and its more severe form Acute Respiratory Distress Syndrome (ARDS) was well tolerated and significantly reduced the all cause mortality in patients at day 28.
“Two of the early pathophysiological events in ALI/ARDS that affect lung function are vascular leakage and escalation of inflammation. Both these events can be modulated by locally active adenosine, the enzymatic end product of the FP-1201 target gene CD73,” says Dr. Geoff Bellingan from University College London Hospitals (UCLH), who also is the Principle Investigator of the FPCLI001 study. “The results of the FPCLI001 study support the hypothesis that modulation of vascular leak and inflammation may reduce mortality in ALI/ARDS,” comments Dr. Bellingan.
Faron Pharmaceutical Ltd. is a privately owned clinical stage drug discovery and development company in Turku, Finland. Faron has three major drug development projects focusing on acute trauma, incipient vasculopathies, inflammatory diseases, and cancer/metastasis growth. Faron is currently expanding the FP-1201 program to a pan-European pivotal phase III study that the company hopes to get started in 2012.
Sources: Turun Sanomat, Faron Pharmaceutical Ltd